2008 Publications

Originals

  1. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Sala M, Varela M, Llovet JM, Bru C, Bruix J.Diagnosis of hepatic nodules < 20 mm in cirrhosis. Prospective validation of the AASLD guidelines for Hepatocellular Carcinoma (HCC). Hepatology 2008; 47: 97-104.

  2. Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Akita K, Shirasawa S, Sasazuki T, Margignetti J, Llovet JM, Friedman S.  Ras Promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008;134:1521-31.

  3. Llovet, JM , Di Bisceglie A, J Bruix J, Kramer B, Lencioni R, Zhu A, Sherman M, Schwartz M, Lotze M, Talwalkar J, and Gores GJ on behalf of Panel of Experts in HCC. Design and end-points of clinical trials in HCC. Journal of National Cancer Institutes 2008;100: 698-711.

  4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Cosme A, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten T, Galle P, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J, for the SHARP Investigators Study Group*. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008; 359:378-390

  5. Schwartz  M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein S, Martignetti J, Marsh W, Llovet JM. Liver Transplantation for hepatocellular carcinoma: extended indications based on molecular markers. J Hepatol 2008;49:581-8.

  6. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM.. Focal gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma. Cancer Research 2008; 68:6779-88.

  7. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan J, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene Expression Profiles of Adjacent Liver Predict Outcome in Hepatocellular Carcinoma. N Engl J Med. 2008;359:1995-2004.

  8. Villanueva A, De Feo A, Chen Y, Yea S, Fiel I, Thung S, Schwartz M, Roayaie S, Schwartz M, Friedman SL, Llovet JM. Role of dual TKI and an mTOR inhibitor in blocking PI3K pathway in HCC. Gastroenterology 2008; 135:1972-83.

Editorials

  1. Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. J Hepatol. 2008 Jul;49:1-5.

  2. Llovet JM, Lok A. Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1121-3

Reviews

  1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol, 2008;48: S20-S37.

  2. Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-53

  3. Newell P, Villanueva A, Friedman S, Koike K, and Llovet JM. Experimental models in hepatocellular carcinoma. J Hepatol, 2008, 48:858-879.

  4. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.

  5. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib – a multi-kinase inhibitor that targets both Raf and VEGF signaling. Mol Cancer Ther 2008;7:3129-40.